CREATE Medicines closed a $122 million Series B to expand its in vivo immune programming platform across autoimmune disease and oncology. The company highlighted repeat-dose capabilities from its mRNA-LNP approach, reporting more than 50 patients dosed in clinical programs and citing ongoing progress including CRT-402 for CD19-targeted autoimmune B cell depletion and MT-303 in frontline hepatocellular carcinoma.